TP53 and cancer: Moreover, in a pan‐cancer transcriptome analysis using TCGA data, patients with advanced age (>75 years old) not only showed worse OS compared to young patients (<50 years old) in 16 cancer types, including LUAD, but also exhibited unique gene expression changes affecting multiple important pathways implicated in cancer progression including epithelial–mesenchymal transition (EMT), KRAS signaling, p53 pathways, and hypoxia.20